Participated · Equity · Aug 2025

LIZY offers circular electric leasing that re-leases electric vehicles for second or third leasing cycles, targeting smaller businesses. Founded in 2019 and based in Brussels, it has expanded into France and the Netherlands. The company doubled its headcount to 60 and achieved a +100% increase in turnover by 2024. LIZY argues electrification makes multi-cycle leasing viable because electric vehicles last longer and require less maintenance, increasing environmental benefits as vehicles are used for longer. Management says the new financing will let it roll out its concept faster internationally and promote its circular approach across Europe. Investors and founders have framed the company's original positioning and ambition as drivers of its strong growth. Lizy is a Brussels-based startup that streamlines leasing of second-hand vehicles for solo entrepreneurs, freelancers and small business owners. The platform emphasizes shorter contracts and lower fees to make leasing more accessible. To date about 1,500 companies across Belgium have leased vehicles using Lizy's platform. The company secured a €40 million financing package comprising around €8.5 million in equity and €32 million in debt to boost growth. Investors in the package include Alychlo (the family investment company of Marc Coucke), D'Ieteren Group and VC firm New Alpha. Lizy is planning international expansion across Europe, targeting France, Germany and the UK.

Participated · Series D · Dec 2024

miDiagnostics develops silicon chip–based qPCR diagnostics that deliver miniaturized, rapid, lab-quality tests directly to patients and clinicians. Its platform integrates a nanofluidic processor on a chip with a compact reader to measure a wide array of biomarkers from minimally invasive samples. The company intends to use the funds to accelerate development of a sterility test for batch release and related quality‑control tests for the BioPharma industry using its proprietary qPCR technology. miDiagnostics raised €30M in a Series D round led by Thermo Fisher Scientific, with participation from Alychlo, VMF Invest and Pamica. Founded in 2015, the company emerged from imec’s R&D hub in collaboration with Johns Hopkins University. miDiagnostics is led by CEO Katleen Verleysen and is based in Leuven, Belgium. miDiagnostics develops a next-generation diagnostic platform based on a silicon nanofluidic processor for point-of-care testing. The platform aims to miniaturise and simplify the diagnostics process to reduce costs and enable rapid, comprehensive health analysis. In response to the coronavirus crisis the company adapted R&D toward an ultrafast PCR test for SARS-CoV-2 intended to deliver PCR accuracy with the speed of rapid antigen tests. Field tests have begun, including trials at Brussels Airport, and the company planned a product launch in spring next year. Financially, miDiagnostics signed a €20M loan agreement with the European Investment Bank supported by the European Commission under the InnovFin Infectious Diseases Finance Facility. The funds will be used to scale up processes, accelerate market launch, and support R&D targeting infectious diseases. miDiagnostics develops an ultra-fast point-of-care PCR test that combines lab-quality PCR accuracy with speeds reported to be about 20 times faster than traditional lab PCR machines. The test uses a PCR testcard read by a compact reader and is built on a nanofluidic silicon‑chip diagnostics platform developed by imec and licensed to miDiagnostics in collaboration with Johns Hopkins University. The company is negotiating its first commercial collaborations, finalizing supplier agreements to scale production, and plans pilot programs shortly after summer. miDiagnostics is also discussing commercialization of a rapid PCR‑based breath test for COVID‑19 recently developed by imec, and it intends to develop a broader portfolio of screening, diagnostic and monitoring tests. The firm accelerated its commercial transition after raising €58 million in additional funding, bringing total capital raised since 2015 to €140 million. Management was reinforced with Katleen Verleysen as CEO and Hans Vanderwegen as COO to lead commercial roll‑out and production scaling. miDiagnostics was spun out of imec and is based in Leuven, Belgium; the company was created in 2015. miDiagnostics is a Leuven-based health tech startup developing a silicon-based nanofluidic processor on a chip paired with a compact reader to run clinical biomarker tests from small samples such as fingerprick blood. CEO Nicolas Vergauwe says the company aims to make "diagnostic information as readily accessible as digital information on a smartphone." The proprietary platform, invented by imec and Johns Hopkins University, claims it can measure virtually any biomarker from easily acquired samples. Target use cases highlighted include home monitoring of chronic patients, fast screening for physicians or remote health centers in developing countries, and widespread monitoring during pandemics. The startup has raised €14 million from existing investors plus Dr. Rudi Pauwels and Dr. Ir. Urbain Vandeurzen to speed development and prepare for industrial-scale manufacturing. The funding is intended to accelerate commercialization of remote clinical testing and scale up chip production.

Led · Equity · Apr 2022

Founded in 2003, Itineris builds software solutions for energy and water companies that help optimise business processes, support environmental objectives, and improve customer relations and end-user experience. The company operates with a staff of over 400 and maintains offices in Europe and the U.S. It reported annual turnover of €60 million in 2021, a 23% increase year-over-year. Itineris has pursued inorganic growth, acquiring Belgian data-platform firm Opinum at the end of 2021. Management says the business is focused on further European and U.S. market expansion and strategic acquisitions. The company aims to play a pioneering role in the energy and digital transition. Itineris provides the UMAX® customer information system (CIS) software to manage a utility company’s customer lifecycle and offers operational software and services for utilities. UMAX is fully integrated with Microsoft ERP platform Dynamics AX and the company is a Microsoft Gold Partner. The company has offices in Deurle, Belgium and a US presence in Marietta, GA, and employs more than 250 people worldwide. Itineris intends to use the $10m funding for product innovation and capabilities expansion, primarily in its core software. The company reported revenues of $39.8m in 2014 and has received $25m in investments to date.

Participated · Series E · Jan 2019

SOPHiA GENETICS offers the SOPHiA DDM platform, which analyzes complex genomic and multimodal data to generate real‑time, actionable insights for hospitals, laboratories, and biopharma institutions. The platform is seeing global clinical adoption, with 463 core genomics customers and recent partnerships including Mayo Clinic going live for hereditary cancer and rare disease testing. In Q1 2024 the company reported $15.8 million in revenue, a 13% year‑over‑year increase, and operating losses of $18.8 million. Management reiterated full‑year 2024 guidance of 25%–30% revenue growth, an adjusted gross margin between 72.5% and 72.7%, and an adjusted operating loss of $45 million to $50 million. The company has arranged financing to support its growth initiatives and operations while continuing to expand access to data‑driven medicine. SOPHiA GENETICS states its mission is to use AI to deliver care for patients with cancer and rare disorders worldwide. SOPHiA GENETICS combines machine learning applied to medical imaging with genomic sequencing to generate a more holistic view of disease and improve care coordination. Its technology integrates multiple sources of medical data to surface novel insights about how diseases spread in the body. The Boston- and Lausanne, Switzerland-based company says its platform is used by more than 1,000 healthcare institutions and has analyzed 600,000 genomic profiles. The firm plans to use new funding to expand its footprint in the U.S. and Asian markets. Leadership changes — including adding former Agilent CFO Didier Hirsch to the board and creating an audit committee — suggest preparation for a potential public offering. The company emphasizes better patient care as its primary goal. Sophia Genetics develops SOPHiA AI, a universal platform that enables healthcare professionals to analyze complex genomic and radiomic data for oncology and hereditary disorders. Led by CEO and founder Dr. Jurgi Camblong, the company combines life sciences and medical expertise with advanced data computing and mathematical capabilities. Sophia Genetics is based in Lausanne, Switzerland, and Boston, MA. Its platform is utilized by more than 850 hospitals across 77 countries and has supported the diagnosis of over 300,000 patients. The company closed a $77M funding round and has now raised a total of $140M. It plans to use the funds to accelerate the reach of its data-driven medicine solutions and add talent to reinforce its presence in the US. Sophia Genetics operates a SaaS big-data analytics platform that aggregates clinician-fed genomic data and applies statistical inference and machine-learning algorithms to improve DNA-sequencing diagnostic accuracy. The platform ingests raw FASTQ data, has been validated on over 340 different sequencers, and has benchmarked samples from more than 10,000 patients and 500,000 unique variants. Hospitals connect and share annotated results so the AI improves as the user base grows — the company says it is adding about 10 new hospitals per month and currently works with over 350 hospitals. Accuracy has improved over time (from ~85% to ~98% in successive 10k-patient cohorts) with reported sensitivity between 99.9%–100% and specificity between 99%–100%. Sophia charges hospitals on a per-analysis, on-demand basis. With cheaper sequencing and richer datasets the company plans to expand analytic layers (for example combining imaging with molecular data) and to push deeper into oncology-case management and multi-modal predictive analyses. The new funding is intended to support global deployment and ramp commercial activity beyond Europe into Latin America, AsiaPac, Canada and the U.S. Sophia Genetics offers the Sophia DDM™ analytics platform, which hosts machine-learning algorithms and a large clinical genomics community to analyze genetic data for cancers and inherited conditions. The company supports more than 100 healthcare institutions across 20 countries, including Oxford University Hospital, Hospices Civils de Lyon, Vall d’Hebron Hospital and Cologne University Hospital. Led by CEO and co-founder Jurgi Camblong, the team comprises about 60 employees, two thirds of whom hold PhDs in genomics, bioinformatics, computational and data protection. Sophia leverages advanced analytics to help more accurately and quickly diagnose thousands of patients. The company plans to use new funding to continue market expansion and broaden its range of genomic tests. The firm has previously received backing from Mike Lynch, founder of Invoke Capital.